Oxymatrine, one of the main active components of extracts from the dry roots of Sophora flavescens, has been reported to possess anticancer activities in vitro and in vivo. However, the precise mechanism involved remains largely unknown. The present study is conducted to investigate the anticancer activity and the underlying mechanisms of oxymatrine in human hepatoma cells in vitro and in vivo. Hep-G2 and SMMC-7721 cells were treated by oxymatrine and subjected to methyl thiazolyl tetrazolium analysis, Hoechst 33342 staining, annexin V/propidium iodide double staining, reverse transcription polymerase chain reaction, and Western blot analysis. In addition, SMMC-7721 xenograft tumors were established in male nude BALB/c mice, and oxymatrine was intravenously administered to evaluate the anticancer capacity in vivo. Our results showed that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in vitro. Furthermore, the RNA and protein expression of Bax and caspase 3 levels were significantly upregulated, whereas the expression of Bcl-2 was downregulated. These protein interactions may play a pivotal role in the regulation of proliferation and apoptosis. More importantly, our in vivo studies showed that administration of oxymatrine decreased tumor growth in a dosedependent manner. Immunohistochemistry analysis demonstrated an increase of Bax and caspase 3 and a decrease of Bcl-2 in tumor tissues following oxymatrine treatment which are consistent with the in vitro results. Taken together, our findings indicated that oxymatrine can inhibit cell proliferation and induce apoptosis of human hepatoma Hep-G2 and SMMC-7721 cells and might offer a therapeutic potential advantage for human hepatoma chemoprevention or chemotherapy.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related mortality worldwide. 1 It has the characteristics of secret coming on, long delitescence, a rapid growth rate, strong malignant, easy invasion and metastasis, bad prognosis, and so on. 2 Owing to the dissemination of hepatitides B and C virus infection, the overall incidence of HCC remains alarmingly high in developing countries and increases steadily in most developed countries. 3, 4 More than 600 000 people die from HCC each year. 5 So far, surgical resection is the most effective treatment of primary liver cancer. Unfortunately, surgery is not always possible due to the size or position of the tumor, and it is also not possible to operate if the cancer has spread beyond the liver. 6 Many patients, who are diagnosed with HCC at its advanced stage, are only candidates for palliative care. 7 Furthermore, since no effective palliative chemotherapy is available, the prognosis of patients with advanced HCC is dismal, and the 5-year relative survival rate is 3% to 5% in most countries. 8 There is thus an urgent need to identify novel therapeutic agents to treat patients with HCC. Nowadays, growing evidences suggest that natural products might be a good source to develop next generation anticancer drugs. 9 So aiming at discovering and developing novel antitumor drugs from natural products with little toxicity or few side effects has become a new trend for the prevention and management of HCC.
Oxymatrine (molecular formula, C 15 H 24 N 2 O 2 ; see Figure 1 ) is one of the key components extracted from Sophora flavescens, a leguminous plant grown in China, Japan, and some European countries, 10 and has attracted much attention because of its low toxicity and side effects. Extensive research over the past decades have revealed various important pharmacological activities of oxymatrine under in vitro and in vivo conditions, including anti-inflammation, immunoregulatory, antihepatitis virus infection, antihepatic fibrosis, antianaphylaxis, and other immune regulation. [11] [12] [13] [14] [15] Recently, oxymatrine has been extensively studied for their cancer chemopreventive potential against various cancers, for instance, human pancreatic cancer, 16 gastric cancer, 17 breast cancer, 18 lung cancer, 19 osteosarcoma, 20 and leukemia. 21 However, the precise mechanisms underlying the anticancer activity of oxymatrine are largely unknown.
The goals of this study were to determine whether oxymatrine could inhibit the growth and induce apoptosis of human hepatoma Hep-G2 and SMMC-7721 cells and, if so, to clarify its molecular mechanism involved in antineoplastic activities, which may offer a promising new approach in the effective treatment of human hepatoma.
Materials and Methods

Reagents and Antibodies
Oxymatrine was purchased from Nanjing Zelang Medical Technology Co, Ltd (Lot Number: ZL10603GZ, Jiangsu, China), and its purity was 98% confirmed by highperformance liquid chromatography. It was dissolved in a complete cell culture medium at a stock concentration of 10 mg/mL and stored at À20 C. The stock solution was freshly diluted in the medium just before the use in each experiment. Materials used included 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Company, St. Louis, California), annexin V-fluorescein isothiocyanate (FITC), Apoptosis Detection kit (MultiSciences Biotech, Shanghai, China), Hoechst 33258 staining assay kit (Molecular Probes, Beyotime Institute of Biotechnology, Shanghai, China), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (Kangchen Bio-tech, Shanghai, China), Bax, Bcl-2, caspase 3, and horseradish peroxidaseconjugated sheep anti-mouse immunoglobulin G (IgG) and sheep anti-rabbit IgG antibodies (Cell Signaling Technology, Danvers, Massachusetts).
Cell Lines and Culture
The human hepatoma cell lines Hep-G2 and SMMC-7721 were purchased from the Shanghai Cell Institute Country Cell Bank. The cells were maintained in Dulbecco's modified Eagle's medium (Gibco, Gaithersburg, Maryland) supplemented with 10% fetal bovine serum (Gibco), 100 mg/mL streptomycin and 100 units/mL penicillin (HyClone Laboratories Logan, Utah, USA), and incubated in a humidified atmosphere with 5% CO 2 at 37 C. Cells were selected to be used in relevant experiments in exponential growth phase.
Cell Proliferation Assay
The effect of oxymatrine on the viability of Hep-G2 and SMMC-7721 cells was measured by MTT assay. Cells were trypsinized and seeded into 96-well plates at a density of 5 Â 10 3 cells/well. The cells were cultured overnight and replaced with fresh medium containing various concentrations (0-2.5 mg/mL) of oxymatrine. Untreated cells served as controls. At different time points (24, 36 , and 48 hours), 20 mL MTT (5 mg/mL) was added to each well followed by a 4-hour incubation. Then the medium was discarded and 150 mL of dimethyl sulfoxide was added to each well to dissolve the resulting formazan crystals. The absorbance values at 490 nm were measured by microenzyme-linked immunosorbent assay plate reader, and the effect on cell growth inhibition was assessed as percentage of cell proliferation inhibition wherein vehicle-treated cells were taken as 0% inhibition. 
Hoechst 33258 Staining
The apoptosis of Hep-G2 and SMMC-7721 cells treated with oxymatrine (0, 0.5, 1.0, and 1.5 mg/mL) was determined by Hoechst staining. Briefly, the cells were exposed to oxymatrine for 36 hours and stained with Hoechst 33258 (10 mg/mL) for 15 minutes. After being washed with phosphate-buffered saline (PBS), the cells were observed using an inverted fluorescence microscope. Apoptotic cells were characterized by nuclear shrinkage, condensation, and fragmentation. Cells from 5 randomly selected microscopic fields were counted. The apoptosis index (AI) of cells was calculated using the following formula: AI (%) ¼ apoptotic cells/total cell Â 100%.
Annexin V-FITC/Propidium Iodide Double Staining
Annexin V-FITC/propidium iodide (PI) double staining was employed to quantify the apoptotic rate of Hep-G2 and SMMC-7721 cells treated with oxymatrine. Briefly, cells were seeded into 6-well plates at 3 Â 10 5 cells/well and exposed to oxymatrine (0, 0.5, 1.0, and 1.5 mg/mL) for 36 hours. The cells were then stained using annexin V-FITC/PI double fluorescence apoptosis detection kit following the manufacturer's instruction. Samples were analyzed using flow cytometry (Becton Dickinson, Franklin Lakes, New Jersey) within 1 hour after the staining. In addition, Hep-G2 and SMMC-7721 cells were treated with or without
Louis, California), a caspase 3 inhibitor, for 1 hour before treatment with oxymatrine for 36 hours, then the apoptosis was analyzed as described earlier.
Reverse Transcription Polymerase Chain Reaction Assay
Hep-G2 and SMMC-7721 cells were seeded into 24-well plates at a density of 1 Â 10 5 cells/well. After 24 hours of culture, cells were treated using 0.5, 1, and 1.5 mg/mL oxymatrine and vehicle for 36 hours. Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, California) according to the manufacturer's recommendations, and first-strand complementary DNA was synthesized from 2 mg of total RNA using PrimeScript Reverse Transcriptase (Takara, Shiga, Japan). The polymerase chain reaction (PCR) primer and regimen are as follows: 5 0 -AGG ATC GAG CAG GGC GAA TG-3 0 and 5 0 -GCT CCC GGA GGA AGT CCA AT-3 0 for Bax, 5 0 -GAT GGC AAA TGA CCA GCA GA-3 0 and 5 0 -GCA GGA TAG CAG CAC AGG AT-3 0 for Bcl-2, and 5 0 -GAC TCT GGA ATA TCC CTG GAC AAC A-3 0 and 5 0 -AGG TTT GCT GCA TCG ACA TCT G-3 0 for caspase 3. The PCR conditions included denaturation at 94 C for 1 minute, annealing at 56 C for 1 minute, and extension at 72 C for 2 minutes. Samples were separated in 20 g/L agarose gel and visualized with ethidium bromide staining under ultraviolet light.
Western Blot Analysis
Hep-G2 and SMMC-7721 cells were treated with oxymatrine (0, 0.5, 1.0, and 1.5 mg/mL) for 36 hours, respectively. Then the cellular proteins were extracted in lysis buffer (1% NP-40, 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, 150 mmol/L NaCl, and 10 mmol/L Tris-HCl) containing 1/100 phenylmethanesulfonyl fluoride solution. Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membrane (Beyotime Institute of Biotechnology). After blocking, the membranes were incubated with primary antibodies overnight at 4 C and then with appropriate secondary antibodies conjugated to horseradish peroxidase for 1 hour at room temperature. After each incubation period, the membranes were washed thrice with Tris Buffered Saline with Tween (TBST) each for 5 minutes. Signals were visualized by electrochemiluminescence. Equal protein loading was assessed by the expression of GAPDH. The bands were semiquantified using Image J software.
In Vivo Efficacy of Oxymatrine
Male BALB/c nude mice at 4 weeks of age (Shanghai SLAC Laboratory Animal Center of Chinese Academy of Sciences, Shanghai, China) were maintained throughout in a specific pathogen-free environment. Exponentially growing SMMC-7721 cells (5 Â 10 6 ) were suspended in 150 mL PBS and subcutaneously injected into the right axillary fossa of each nude mouse. On day 6, a total of 32 nude mice whose tumors were similar in size were chosen and equal numbers were assigned to 4 groups (n ¼ 8/group), Then, the treatment groups were injected 2 doses of oxymatrine (40 and 80 mg/kg) intravenously on alternative days, respectively. Positive and negative control group animals were given 20 mg/kg of 5-fluorouracil (5-Fu) and sterile physiological saline, respectively. Mice were killed on day 27, after these drugs had been administered 7 times, and tumors were dissected and weighed. The dissected tumors were frozen at À80
C for further analysis. The animal studies were approved by the Wujiang No. 1 People's Hospital Ethics Committee, and the principles of laboratory animal care were followed in all animal experiments. The tumor volume was calculated using the formula ''0.5 Â a Â b 2 ,'' in which a and b represent the maximal and minimal diameters. The tumor inhibition ratio was expressed according to the following formula: ([mean tumor weight of control group À mean tumor weight of treated group]/the mean tumor weight of control group) Â 100%.
Then formaldehyde-fixed, paraffin-embedded tissue blocks were prepared from xenograft tissue and cut into serial sections (4 mm) for examining the expression of Bax, Bcl-2, caspase 3, and Ki67 (mouse anti-Ki67 antibody; GeneTex Inc, Irvine, California) by immunohistochemistry using the streptavidin-peroxidase kit (Fuzhou Maixin Biotechnology Development Co, Fuzhou, China). Each slice was enumerated under 5 fields of medium magnification (400Â) to determine the proportion of positive cells.
Statistical Analysis
All data are expressed as mean + standard deviation (SD) and analyzed by the SPSS 17.0 software. Comparisons among different groups were performed using one-way analysis of variance, and a P value less than .05 was considered statistically significant. All experiments presented here were derived from at least 3 independent experiments.
Results
Oxymatrine Treatment Inhibited the Proliferation and Growth of Hep-G2 and SMMC-7721 Cells
Hep-G2 and SMMC-7721 cells were incubated with oxymatrine at various concentrations for 24 to 48 hours, and we found that the growth and proliferation of hepatoma cells decreased in a time-dependent manner ( Figure 2) . The results showed that at a concentration of 0 to 1.5 mg/mL of oxymatrine, the inhibition rate increased sharply. However, higher concentration of oxymatrine had a saturated inhibitory effect. During the following experiment at 36 hours, oxymatrine showed a significantly higher inhibiting effect than that at 24 hours. In contrast, there was no significant difference in cell inhibition rate among prolonged treatment for 48 hours. For Hep-G2 and SMMC-7721 cells, the IC50 (half maximal inhibitory concentration) for oxymatrine at 36 hours was 1.32 and 1.21 mg/mL, respectively. Based on these observations, we selected a dose of 0 to 1.5 mg/mL and a period of 36 hours post-oxyamtrine treatment for further studies.
Oxymatrine Treatment Induced Apoptosis in Hep-G2 and SMMC-7721 Cells
In the present study, morphological changes in the apoptotic cells were revealed by the Hoechst 33258 staining ( Figure 3A and B). In the untreated Hep-G2 and SMMC-7721 cells, the nuclei were stained weakly homogeneously blue, whereas in the group treated with oxymatrine, the cells exhibited strong blue fluorescence and cell nuclei appeared to be highly condensed and crescent shaped, revealing the typical apoptosis characteristics. Next, we quantified oxymatrine-induced apoptosis of human hepatoma cells by flow cytometry assay. The apoptotic rates of the Hep-G2 cells were 25.2% + 2.8%, 32.9% + 3.5%, and 59.7% + 3.2%, respectively, after treatment with 0.5, 1.0, and 1.5 mg/mL oxymatrine, which were all higher than that of untreated cells (7.5% + 2.2%; P < .01); The apoptotic rates of the SMMC-7721 cells were 28.9% + 4.0%, 39.2% + 6.3%, and 66.2% + 5.6%, respectively, after treatment with 0.5, 1.0, and 1.5 mg/mL oxymatrine, which were all higher than that of untreated cells (8.3% + 3.0%; P < .01; Figure 3C and D). These data suggested that oxymatrine induced apoptosis in Hep-G2 and SMMC-7721 cells dose dependently.
Oxymatrine Treatment Induced Apoptosis Through Regulation of Bax/Bcl-2 Ratio and Caspase 3 Activation
To investigate the possible molecular mechanisms responsible for oxymatrine-induced apoptosis in Hep-G2 and SMMC-7721 cells, we evaluated the expression of Bax, Bcl-2, and caspase 3 in cells incubated for 36 hours with with different concentrations of oxymatrine. We also measured the Bax/ Bcl-2 ratio in the protein and messenger RNA (mRNA) levels, and all of the molecules evaluated are known to play important roles in apoptosis. From Western blot analysis, we found that Bax expression increased after exposure to oxymatrine, whereas Bcl-2 expression decreased. The Bax/ Bcl-2 ratio increased significantly in the oxymatrine-treated groups compared with the control group. Moreover, the Polymerase chain reaction was analyzed to detect the mRNA levels of Bax, Bcl-2, and caspase 3. As shown in Figure  5 , the expression of Bax and caspase 3 mRNA was upregulated, whereas the Bcl-2 mRNA level was downregulated in the oxymatrine-treated group. Furthermore, we examined whether apoptosis induced by oxymatrine was affected by Z-DEVD-FMK, a caspase 3 inhibitor. Oxymatrine-induced apoptosis in Hep-G2 and SMMC-7721 cells were partially diminished by the addition of Z-DEVD-FMK ( Figure 4D ), which further confirmed the participation of caspase 3.
Oxymatrine Treatment Inhibited the Tumor Growth In Vivo
To further investigate the effects of oxymatrine on tumor growth in vivo, the xenograft model was established in BALB/c nude mice following subcutaneous transplantation of SMMC-7721 cells. As shown in Figure 6A -C, administration of 40 and 80 mg/kg of oxymatrine resulted in a significant regression of tumor weight, and the inhibitory rates were 39.4% and 63.7%, respectively. The inhibition levels of tumor volume between 40 and 80 mg/kg oxymatrinetreated groups are also statistically significant (P < .05). The 20 mg/kg 5-Fu-treated mice had the smallest tumor weight and volume among 4 groups. Further, the subcutaneous tumor tissues were examined by hematoxylin and eosin staining. The tumor tissue from control mice showed disorganized arrangement. The ratios of nucleus to cytoplasm were increased, and nuclei showed clear signs of heteromorphism. In contrast, in tumor tissues from mice treated with oxymatrine or 5-Fu, the ratio of nucleus to cytoplasm was reduced, and the nuclei were polygonal and lightly stained ( Figure 7A ). In addition, the expressions of Bax, Bcl-2, caspase 3, and Ki67 in oxymatrine-treated tumors were examined by immunohistochemistry. As shown in Figure 7B -K, the mean areas that stained positively for Bax and caspase 3 were upregulated, whereas Bcl-2 and Ki 67 were downregulated compared with those of the negative control group (P < .05). These results indicated that oxymatrine has a significant antihepatoma effect in vivo.
Discussion
Oxymatrine has been shown to exhibit various pharmacological activities, and in recent years, studies have shown that oxmatrine can inhibit the growth of a variety of tumor cells as well as induce cell apoptosis and cycle arrest in some tumors. 6, [21] [22] [23] However, little is known about its effects on human hepatoma, and the precise mechanism involved remains largely unknown. Therefore, in this study, we proved the anticancer effects of oxymatrine on human hepatoma Hep-G2 and SMMC-7721 cells and explored the related molecular mechanisms.
Uncontrolled proliferation is a key aspect of tumorigenesis, and inhibiting cell proliferation can achieve growth arrest in tumor cells. Cell apoptosis is an autonomous cell death process. During the process, apoptosis is characterized by cell shrinkage, chromatin condensation, blebbing of the plasma membrane, and nuclear condensation without cell lysis. 21, 24 Apoptosis can be induced by a variety of physical and chemical factors and drugs. 25 Since deregulation of apoptosis is the hallmark of all cancer cells, 26 the induction of apoptosis has been described as a standard and best strategy in anticancer therapy. 27, 28 Clearly, an agent which could efficiently inhibit the proliferation and induce apoptosis of cancer cells would be a hopeful candidate to suppress cancer progression and thus could reduce mortality. Therefore, we examined whether oxymatrine could inhibit proliferation and induce apoptosis of human hepatoma cell lines Hep-G2 and SMMC-7721. Results from MTT, Hoechst 33342 staining, and annexin V-FITC/PI staining suggested that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in the range of 0.5 to 1.5 mg/mL.
To elucidate the molecular mechanisms as to how oxymatrine inhibits proliferation and induces apoptosis of human Figure 5 . The effect of oxymatrine on the messenger RNA (mRNA) expression of Bax, Bcl-2, and caspase 3. A, An upregulation in the mRNA levels of Bax, caspase 3, and a downregulation of Bcl-2 occurred in Hep-G2 and SMMC-7721 cells after treatment with various concentrations of oxymatrine for 36 hours. B and C, The band density ratio of Bax to Bcl-2 and caspase 3 to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was shown as the means + standard deviation (SD). *P < .05, versus the control group; **P < .01, versus the control group.
hepatoma Hep-G2 and SMMC-7721 cells, we investigated changes in several related proteins in oxymatrine-treated and nontreated cells. It is reported that apoptosis is initiated by 2 principal pathways: the mitochondria-mediated intrinsic pathway and the death receptor-induced extrinsic pathway. 29 Mitochondria play a central role in apoptosis. During mitochondria dysfunction, proteins in the Bcl-2 family play a central role because they control mitochondrial permeability following mitochondrial dysfunction. 30 The Bcl-2 family members can be classified into 3 subfamilies, proapoptotic members such as Bax, Bad, Bid, and Bcl-Xs; anti-apoptotic members such as Bcl-2 and Bcl-xL, and the BH3-only members such as Bim and Bad. 31 The relative balance between these anti-and proapoptotic Bcl-2 family members influences the susceptibility of cells to a death signal. Increasing levels of Bax generate cell death signals, whereas Bcl-2 is the dominant inhibitor of Bax; thus, the induction of apoptosis is influenced by the Bcl-2/Bax ratio. 32 In this study, we found that after dealing with different concentrations of oxymatrine, the expression of Bax and Bcl-2 was significantly altered at both the RNA and the protein levels. Moreover, the Bax/Bcl-2 ratio increased 5.7-fold and 9.1-fold, respectively, in Hep-G2 and SMMC-7721 cells. These results together with the present reports indicate that an increased Bax/Bcl-2 ratio is associated with oxymatrine-induced apoptosis in human hepatoma cells.
The cysteine proteases of the caspase family also play a key role in the execution phase of apoptosis, 33 and both intrinsic and extrinsic pathways can activate caspases. Caspase 3 is considered the key caspase for apoptosis as Fu) ; negative, sterile physiological saline). Oxymatrine significantly reduced the tumor growth in vivo. One representative mouse from each group is shown. B and C, The tumor weight and volume in the each group. *P < .05, versus the control group; **P < .01, versus the control group; # P < .05, versus the 40 mg/kg oxymatrine-treated group.
activated caspase 3 leads to final destruction of the target cell. Not only does caspase 3 mediate apoptosis in many human cells, it has also been experimentally shown to induce apoptosis in a myriad of ways, such as by cleaving DNA repair molecules, skeleton proteins, extracellular matrix proteins, and degrading anti-apoptosis proteins and other related molecules. 34 In this study, we have shown that the levels of activated caspase 3 of Hep-G2 and SMMC-7721 cells induced by oxymatrine were increased in a dose-dependent manner. The activation of caspase 3 occurred concomitantly with apoptosis in Hep-G2 and SMMC-7721 cells, suggesting that the activation of caspase 3 might lead to apoptosis. This viewpoint was further verified by the addition of Z-DEVD-FMK, a caspase 3 inhibitor. Combined with 1.5 mg/mL oxymatrine and 5 mM Z-DEVD-FMK, apoptosis was partially blocked. These results indicated that oxymatrine-induced apoptosis in Hep-G2 and SMMC-7721 cells was partially dependent on the activation of caspase 3.
In addition, in our in vivo study, we found that oxymatrine (40 and 80 mg/kg) significantly inhibited the tumors weight and volume during the treatment period. Furthermore, immunohistochemical analysis confirmed the upregulation of Bax and caspase 3, and downregulation of Bcl-2 and Ki67 following treatment with oxymatrine in vivo, which were consistent with our findings in vitro.
In conclusion, the present investigation confirms that oxymatrine exerts a significant antihepatoma effect both in vitro and in vivo. Moreover, our data showed that the 400Â) . B-E, The expression of caspase 3, Bax, Bcl-2, and Ki67 in xenograft tumors was analyzed by immunohistochemistry (original magnification, 400Â). H-K, Expression of caspase 3, Bax, Bcl-2, and Ki67 was quantified in percentages of positive cells within 5 medium power fields under a microscope and showed in histograms. *P < .05, versus the control group; **P < .01, versus the control group.
anticancer activity of oxymatrine could be attributed to its inhibition of proliferation and induction of apoptosis through the activation of the mitochondria-mediated apoptosis pathway. The dramatic effects of oxymatrine in human hepatoma cells indicated that oxymatrine could be recognized to be a useful candidate as chemotherapeutic agent against human hepatoma.
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